trial · primary record
pimavanserin tartrate
Parkinson's Disease Psychosis
| Phase | Phase 3 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 248 |
| Primary completion | 2026-02-01 |
| Primary endpoint | The primary outcome is change in total SAPS-PD score from baseline to day 43. |
| Registry ID | NCT06068465 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:44:54.077Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06068465
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Pimavanserin Tartrate · approval
- pimavanserin tartrate · compound